Aktienanalyse zu Arcturus Therapeutics Holdings Inc (ARCT)ARCTArcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arcturus Therapeutics (ARCT) is a good buy right now due to its recent positive clinical trial results for ARCT-810, which showed promising safety and efficacy, and the stock's current price of $10.34 being significantly below analyst price targets of $20. The RSI is at a low 23.36, indicating potential for a rebound. However, the company has reported substantial net losses, with a net income of -$23,785,000 in Q2 2026, which remains a risk.

3 analysts cover ARCT: 1 rate it Buy, 1 Hold and 1 Sell. The average price target is 14.00.